NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the ...

View Our Latest Stock Report on Akero Therapeutics Akero Therapeutics Stock Down 2.0 % The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The ...

Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across ...

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the company ...

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...

NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

Uncertainties surrounding the U.S. pharmaceutical sector and the turbulent development in global stock markets have led to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO ), please contact Fletcher Moore by email at ... or (212) 709-8245. You may be able to seek monetary damages, corporate governance ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other small-cap biotech stocks. The biotechnology sector is expanding quickly due to ...